MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. 2013

Keun Hur, and Yuji Toiyama, and Masanobu Takahashi, and Francesc Balaguer, and Takeshi Nagasaka, and Junichi Koike, and Hiromichi Hemmi, and Minoru Koi, and C Richard Boland, and Ajay Goel
Gastrointestinal Cancer Research Laboratory, Baylor Research Institute and Sammons Cancer Center, Baylor University Medical Center, Dallas, TX 75246, USA.

OBJECTIVE Distant metastasis is the major cause of cancer-related death in patients with colorectal cancer (CRC). Although the microRNA-200 (miR-200) family is a crucial inhibitor of epithelial-to-mesenchymal transition (EMT) in human cancer, the role of miR-200 members in the pathogenesis of metastatic CRC has not been investigated. METHODS Fifty-four pairs of primary CRC and corresponding matched liver metastasis tissue specimens were analysed for expression and methylation status of the miR-200 family members. Functional analysis of miR-200c overexpression was investigated in CRC cell lines, and cells were analysed for proliferation, invasion and migration. Expression of several miR-200c target genes (ZEB1, ETS1 and FLT1) and EMT markers (E-cadherin and vimentin) in CRC cell lines and tissue specimens was validated. RESULTS Liver metastasis tissues showed higher expression of miR-200c (primary CRC = 1.31 vs. liver metastasis = 1.59; p = 0.0014) and miR-141 (primary CRC = 0.14 vs. liver metastasis = 0.17; p = 0.0234) than did primary CRCs, which was significantly associated with hypomethylation of the promoter region of these miRNAs (primary CRC = 61.2% vs. liver metastasis = 46.7%; p < 0.0001). The invasive front in primary CRC tissues revealed low miR-200c expression by in situ hybridization analysis. Transfection of miR-200c precursors resulted in enhanced cell proliferation but reduced invasion and migration behaviours in CRC cell lines. Overexpression of miR-200c in CRC cell lines caused reduced expression of putative gene targets, and resulted in increased E-cadherin and reduced vimentin expression. The associations between miR-200c, target genes and EMT markers were validated in primary CRCs and matching liver metastasis tissues. CONCLUSIONS miR-200c plays an important role in mediating EMT and metastatic behaviour in the colon. Its expression is epigenetically regulated, and miR-200c may serve as a potential diagnostic marker and therapeutic target for patients with CRC.

UI MeSH Term Description Entries
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008297 Male Males
D008745 Methylation Addition of methyl groups. In histo-chemistry methylation is used to esterify carboxyl groups and remove sulfate groups by treating tissue sections with hot methanol in the presence of hydrochloric acid. (From Stedman, 25th ed) Methylations
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D014162 Transfection The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES. Transfections
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers

Related Publications

Keun Hur, and Yuji Toiyama, and Masanobu Takahashi, and Francesc Balaguer, and Takeshi Nagasaka, and Junichi Koike, and Hiromichi Hemmi, and Minoru Koi, and C Richard Boland, and Ajay Goel
January 2017, OncoTargets and therapy,
Keun Hur, and Yuji Toiyama, and Masanobu Takahashi, and Francesc Balaguer, and Takeshi Nagasaka, and Junichi Koike, and Hiromichi Hemmi, and Minoru Koi, and C Richard Boland, and Ajay Goel
August 2013, Oncology reports,
Keun Hur, and Yuji Toiyama, and Masanobu Takahashi, and Francesc Balaguer, and Takeshi Nagasaka, and Junichi Koike, and Hiromichi Hemmi, and Minoru Koi, and C Richard Boland, and Ajay Goel
February 2019, Journal of cellular physiology,
Keun Hur, and Yuji Toiyama, and Masanobu Takahashi, and Francesc Balaguer, and Takeshi Nagasaka, and Junichi Koike, and Hiromichi Hemmi, and Minoru Koi, and C Richard Boland, and Ajay Goel
March 2018, Molecular therapy. Nucleic acids,
Keun Hur, and Yuji Toiyama, and Masanobu Takahashi, and Francesc Balaguer, and Takeshi Nagasaka, and Junichi Koike, and Hiromichi Hemmi, and Minoru Koi, and C Richard Boland, and Ajay Goel
June 2018, European review for medical and pharmacological sciences,
Keun Hur, and Yuji Toiyama, and Masanobu Takahashi, and Francesc Balaguer, and Takeshi Nagasaka, and Junichi Koike, and Hiromichi Hemmi, and Minoru Koi, and C Richard Boland, and Ajay Goel
April 2005, Cancer biology & therapy,
Keun Hur, and Yuji Toiyama, and Masanobu Takahashi, and Francesc Balaguer, and Takeshi Nagasaka, and Junichi Koike, and Hiromichi Hemmi, and Minoru Koi, and C Richard Boland, and Ajay Goel
January 2022, Genes,
Keun Hur, and Yuji Toiyama, and Masanobu Takahashi, and Francesc Balaguer, and Takeshi Nagasaka, and Junichi Koike, and Hiromichi Hemmi, and Minoru Koi, and C Richard Boland, and Ajay Goel
October 2010, American journal of translational research,
Keun Hur, and Yuji Toiyama, and Masanobu Takahashi, and Francesc Balaguer, and Takeshi Nagasaka, and Junichi Koike, and Hiromichi Hemmi, and Minoru Koi, and C Richard Boland, and Ajay Goel
December 2022, Molecular therapy. Nucleic acids,
Keun Hur, and Yuji Toiyama, and Masanobu Takahashi, and Francesc Balaguer, and Takeshi Nagasaka, and Junichi Koike, and Hiromichi Hemmi, and Minoru Koi, and C Richard Boland, and Ajay Goel
March 2014, Chinese journal of cancer,
Copied contents to your clipboard!